Morphic Holding (NASDAQ:MORF) Given $32.67 Average Target Price by Analysts

Shares of Morphic Holding (NASDAQ:MORF) have received an average broker rating score of 1.00 (Strong Buy) from the four analysts that cover the company, Zacks Investment Research reports. Four equities research analysts have rated the stock with a strong buy recommendation.

Brokers have set a one year consensus price target of $32.67 for the company and are anticipating that the company will post ($0.45) EPS for the current quarter, according to Zacks. Zacks has also assigned Morphic an industry rank of 85 out of 255 based on the ratings given to its competitors.

A number of equities research analysts recently weighed in on MORF shares. Zacks Investment Research upgraded Morphic from a “sell” rating to a “hold” rating in a research report on Tuesday. Wells Fargo & Co initiated coverage on Morphic in a research note on Monday, July 22nd. They issued an “outperform” rating on the stock. Jefferies Financial Group assumed coverage on Morphic in a research note on Monday, July 22nd. They issued a “buy” rating on the stock. BMO Capital Markets upped their price target on Morphic from $30.00 to $32.00 and gave the stock an “outperform” rating in a research note on Tuesday, August 13th. Finally, Cowen reaffirmed a “buy” rating on shares of Morphic in a research note on Monday, August 12th.

Shares of Morphic stock traded up $0.26 during trading on Friday, reaching $14.94. 23,207 shares of the company’s stock were exchanged, compared to its average volume of 118,485. Morphic has a 1-year low of $14.12 and a 1-year high of $33.50. The company has a 50-day simple moving average of $18.90.

Morphic (NASDAQ:MORF) last posted its quarterly earnings results on Monday, August 12th. The company reported ($4.73) EPS for the quarter, missing analysts’ consensus estimates of ($0.40) by ($4.33). The firm had revenue of $5.57 million during the quarter, compared to the consensus estimate of $8.60 million. As a group, research analysts anticipate that Morphic will post -2.78 earnings per share for the current year.

Several institutional investors have recently bought and sold shares of MORF. Artal Group S.A. purchased a new stake in shares of Morphic in the second quarter worth $9,910,000. Jefferies Group LLC purchased a new position in shares of Morphic in the second quarter worth about $2,478,000. Novo Holdings A S purchased a new position in shares of Morphic in the second quarter worth about $52,433,000. Monashee Investment Management LLC bought a new stake in shares of Morphic in the second quarter worth about $1,498,000. Finally, EcoR1 Capital LLC bought a new stake in shares of Morphic in the second quarter worth about $44,928,000.

About Morphic

Morphic Holding, Inc, a biopharmaceutical company, focuses on the discovery and development of oral small-molecule integrin therapeutics. The company's lead product candidates in clinical development are MORF-720, a selective oral avb6 specific integrin inhibitor for the treatment of idiopathic pulmonary fibrosis; and a4b7 specific integrin inhibitors for the treatment of inflammatory bowel disease.

Recommended Story: Institutional Investors

Get a free copy of the Zacks research report on Morphic (MORF)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Morphic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Morphic and related companies with MarketBeat.com's FREE daily email newsletter.